39. Melman A, Davies K, McCullough A, Bar-Chama N, Christ G. Long-term safety follow-up of a phase 1 trial for gene transfer therapy of ED with hMaxi-K. J Urol. 2008;179(suppl 4):426. 40. Payne RE, Sadovsky R. Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007;74(suppl 3):S47-S53. 41.
DESCRIPTION (provided by applicant): This grant application is by Ion Channel Innovations, LLC, (ICI) a company dedicated to the development of naked DNA transfer to treat the unmet needs of people with common smooth muscle diseases that negatively impactthe quality of life of millions. hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a Urovant disclaims any obligation to update these forward-looking statements, except as may be required by law. Sep 24, 2018 · Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for Aug 28, 2018 · - Urovant expects to initiate Phase 2 hMaxi-K study in 2019 BASEL, Switzerland and IRVINE, Calif., Aug. 28, 2018 /PRNewswire/ -- Urovant Sciences , a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced it has licensed a novel investigational gene therapy for patients with overactive hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive bladder symptoms. Ion Channel Innovations completed the Phase 1b study in 2017 and found hMaxi-K to be generally well tolerated.
Sep 24, 2018 · Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for
This gene therapy involves injection of a transfer gene, calcium-sensitive potassium channel (hMaxi-K), into the penis. I was so confuse and don't know what to do, so I visited the INTERNET for help and I saw a testimony on how a spell caster help them to get their ex back so I contact the spell caster and explain my problems to him..
40. Long-Term Results of a Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Potential Activity of Escalating Doses of hMaxi-K Gene Transfer in Female Participants with Overactive Bladder and Detrusor Overactivity Page S16 Download PDF
hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive bladder symptoms. Ion Channel Innovations completed the Phase 1b study in 2017 and found hMaxi-K to be generally well tolerated. September 30, 2018 March 31, 2018 Assets (Note 2) Current assets: Cash $ 1,659 $ 7,194 Nov 12, 2018 · Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy.